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Patient and GP experiences of pathways to
diagnosis of a second primary cancer: a
qualitative study
Debbie Cavers1* , Rhona Duff2, Annemieke Bikker1, Karen Barnett3, Lovney Kanguru4, David Weller1,
David H. Brewster1 and Christine Campbell1
Abstract
Background: More people are surviving a first primary cancer and experiencing a second, different cancer.
However, little is known about the diagnostic journeys of patients with second primary cancer (SPC). This study
explores the views of patients and general practitioners (GPs) on their experiences of pathways to diagnosis of SPC,
including the influence of a previous diagnosis of cancer on symptom appraisal, help-seeking and referral decisions.
Methods: Qualitative interviews with patients with a SPC diagnosis and case-linked GP interviews in a Scottish
primary care setting. In-depth face to face or telephone interviews were conducted, underpinned by a social
constructionist approach. Interviews were transcribed and Braun and Clarke’s thematic analysis undertaken. Three
analysts from the research team read transcripts and developed the coding framework using QSR NVivo version 10,
with input from a fourth researcher. Themes were developed from refined codes and interpreted in the context of
existing literature and theory.
Results: Interviews were conducted with 23 patients (aged 43–84 years) with a SPC diagnosis, and 7 GPs. Five
patient themes were identified: Awareness of SPC, symptom appraisal and help-seeking, pathways to diagnosis,
navigating the healthcare system, and impact of SPC. GPs interviews identified: experience and knowledge of SPC and
referrals and decision-making.
Conclusions: Insights into the pathway to diagnosis of SPC highlights the need for increased awareness of and
vigilance for SPC among patients and healthcare providers (HCPs), and emotional support to manage the
psychosocial burden.
Keywords: Second primary cancer, Qualitative, Pathways to diagnosis, Survivorship, Primary health care, General
practice
Background
The number of people surviving cancer is increasing [1]
and, in combination with an ageing population, the inci-
dence of second primary cancers (SPCs) will also inevitably
rise [2]. Within the context of cancer survivorship,
recurrence and metastatic disease research, there is a small
but growing literature on SPC [3–5]. Research on SPC to
date has focused on incidence, risk (from environmental,
lifestyle and genetic factors), and late treatment effects fol-
lowing a first primary cancer (FPC) e.g. [6–8]. The reported
risk of developing SPC among cancer survivors ranges from
1 and 17% depending on the index cancer site e.g. [7–9]. A
West of Scotland cancer registry study reported that among
57,393 cancer survivors, 5 % were diagnosed with SPC
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within 5 years of their first diagnosis [10]. SPCs are
estimated to account for as much as 16–18% of total cancer
incidence [11–13].
Relatively little is known about pathways to diagnosis
of SPC. The Pathways to Treatment Model (see Fig. 1)
highlights the complexities of multiple patient factors
- including psychological features and prior experiences -
in influencing symptom appraisal and help-seeking be-
haviours, which may also be applicable to SPCs [14].
The limited evidence suggests that although fear of a
second cancer has been identified as a source of worry
and psychosocial distress [4], there is a general lack of
awareness regarding risk of SPC [5]. There is a need for
greater understanding of differences between diagnostic
journeys for recurrence of FPC versus a second, different
cancer, and their associated psychological dynamics.
There are implications for awareness-raising and, if ap-
propriate, designing behavioural interventions to facili-
tate early detection of SPC [4, 15].
Further, there are challenges for primary care in
managing cancer follow-up, and SPCs will be an in-
creasing feature of this care [5, 16–18]. Not enough
is known about the impact on primary care of a
growing burden of complex disease, including second
and subsequent primary cancers [19]. Exploring the
extent to which the policy drive for early detection
and treatment of cancer applies to SPC in its current
form is warranted [2, 20].
Understanding cancer survivors’ lived experiences of
SPC and their pathways to diagnosis, as well as the per-
spectives of general practitioners (GPs) managing them,
will contribute to the growing evidence base on best
practice in cancer survivorship care.
Aims and objectives
This study aimed to examine: 1) experiences of people
diagnosed with SPC, 2) the influence of a previous ex-
perience of cancer on the SPC diagnostic pathway, in-
cluding symptom appraisal and help-seeking, and 3)
experiences and challenges of diagnosing SPC from the
GP perspective.
Methods
The study involved a series of in-depth interviews
carried out in 2018 with patients diagnosed with SPC
in Scotland, and the GPs involved in diagnosing and
managing SPCs. The study was based on a social con-
structionist approach and conducted by a research
team comprised of clinical and academic health ser-
vice researchers experienced in researching pathways
to diagnosis and early detection of cancer. This article
has followed the COREQ reporting guidelines (see
supplementary file 1).
Participants
Participants were patients who have had a diagnosis
of SPC of the four main cancer types (breast, bowel,
lung and prostate) within the previous 6 months,
where the SPC is defined as a new cancer in the
same or a different anatomical site but with different
pathology to the FPC [21]. Interviews were also
sought with patients’ main GPs.
Fig. 1 Pathways to treatment model [14]
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Recruitment and sampling
Patients were identified from the Scottish Cancer Regis-
try, by NHS staff working for National Services Scot-
land’s Electronic Data Research and Innovation Service
(eDRIS). Recruitment packs (information sheet, consent
form and reply slip) were sent with a covering letter to
eligible patients’ GPs to confirm diagnosis and screen for
suitability. To protect patient confidentiality, GPs were
asked to forward the packs to appropriate patients. In-
terested patients returned a reply slip and consent form
to the researcher (AB, an experienced health services
and qualitative researcher with a background in social
anthropology) who contacted them to build rapport, dis-
cuss the study, and arrange an interview. Due to chal-
lenges in recruiting this select group, all eligible patients
who responded were interviewed. However, the partici-
pants were diverse in terms of gender, location and can-
cer types. No one withdrew from the study. With patient
consent, GPs were then invited for interview (see Fig. 2 -
recruitment process).
Interviews
Interviews were one-off and semi-structured, using
open-ended questions and a patient-centred approach to
explore patient experiences of both first and second pri-
mary cancer, including psychosocial dimensions of ex-
perience and pathways to diagnosis. The topic guide was
developed (for this study) in the first instance by AB and
refined with input from DC, CC and a patient represen-
tative, using their experience of interviewing on the topic
of pathway to diagnosis and living with cancer as well as
a patient perspective (see supplementary file 2). Written
consent was given prior to, and checked before, the
interview commencing. Interviews were face to face in
patients’ own homes, in a university meeting room, or
by telephone, lasting approximately 1 h. Participants
were aware of the objective of the study and that AB
was a health services researcher from a non-medical
background. Field notes were taken and used to inform
subsequent analysis and aid reflexivity.
Face to face and telephone interviews were carried out
with case-linked GPs (including specific discussion of
the patient’s case if relevant).
Analysis
All interviews were digitally recorded, transcribed and
anonymised before being uploaded to QSR Nvivo ver-
sion 10 (www.qsrinternational.com). Data were subject
to Braun and Clarke’s thematic analysis [22]. Transcripts
were read by three researchers (RD, DC and CC with
additional input from AB, thus ensuring triangulation
and rigour in the analytic approach), and re-read for the
purposes of familiarisation; looking for emergent and re-
current concepts. Appraisal across data compared and
contrasted to establish common codes. Codes were then
applied back across the data to ensure that no new codes
or concepts were apparent, such that a level of data sat-
uration was reached. In addition, through an iterative
process of analysis of patient interviews, no new themes
were apparent with subsequent interviews, suggesting a
sufficient sample size for thematic saturation, although
we acknowledge the limitations of this notion and recog-
nise that the concept of saturation has been problema-
tised in the literature [23]. Limitations of recruitment to
GP interviews and subsequent saturation are expanded
on in the discussion. Any deviation from core themes
was explored and interpreted by the research team and
consensus was reached among analysts. Findings were
considered, developed and reported as themes in the
context of existing theory and research, including the
Pathways to Treatment model. Due to time and other
resource constraints, a summary of the analysis was not
returned to participants for member checking.
Results
Patient interviews
Of 23 people interviewed, 20 met the final inclusion cri-
teria (see Table 1); 15 women and five men, ranging in
age from 43 to 84 years. Time between first and second
diagnoses ranged from 1 to 34 years. Ten participants
were diagnosed by presenting to primary care with
symptom concerns, while the remainder had their can-
cers detected incidentally, through screening or during
specialist follow-up for their FPC. All participants had at
least one form of comorbidity.
A number of central themes evident in the data are
reported. Additional supporting quotes for some themes
relating to patient interviews can be found in Table 2.
Awareness of SPC
Overall, there was low awareness among patients about
the risk of developing SPC. SPC diagnosis came as a big
shock to many,
“It was totally unexpected because I didn’t realise
that you could have two cancers running at the
same time.” P11
Patients were more likely to fear recurrence of their
FPC. In some cases, however, there had been such a long
interval between their diagnoses that their FPC had re-
ceded in significance or, in one case, they had forgotten
about it altogether.
SPC was not something that was reportedly discussed
with their GP or oncologist during treatment or follow-
up of the FPC and, on the whole, participants did not
think it influenced the timeliness of their referral for
their SPC (something that was echoed in GP interviews).
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Fig. 2 Patient and GP recruitment process
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1★ M, 70–74 Bowel GP consult 20 years Prostate Incidental Atrial fibrillation, B12 deficiency
2 F / 65–69 Bowel Incidental 19 years Breast Nurse Consult Ileostomy problems for 7 years+, C.
difficile
3 F / 40–44 Cervical Screening 15 years Breast GP consult RTx damage to bowel, early menopause
4 M / 60–
64
Kidney GP consult 24 years Prostate GP consult Cirrhosis, E. coli
5 F / 60–64 Melanoma GP consult 16 years Bowel GP consult High blood pressure
6 F / 70–74 Breast GP consult 3 years Bowel Screening High blood pressure, seroma
7(8) F / 70–74 Breast Incidental 34 years Bowel GP consult Peripheral neuropathy, asthma
8(9) F / 65–69 Pancreatic GP consult 10 years Breast Screening Chronic fatigue syndrome, fibromyalgia
9(11) F / 70–74 Breast Screening 7 years Lung GP non-cancer Osteoporosis
10(13) F / 60–64 Endometrial GP consult 20 years Colorectal GP consult RTx damage, bladder problems, MRSA
11(14) F / 60–64 Lymphoma GP consult 9 years Lung Incidental – via FPC Arthritis
12(15) M / 70–
74
Larnyx Incidental 3 years Prostate GP consult Back pain




1 year Lung Incidental – via FPC Diabetes, Macular degeneration
14(17) F / 75–79 NHL Incidental 5 years Bowel Secondary care
consult
Heart condition
15(18) F / 80–84 NHL Emergency 5 years Breast Breast clinic COPD
16(19) F / 60–64 Breast Screening 6 years Colon GP consult Underactive thyroid, peripheral
neuropathy
17(20) F / 60–64 Melanoma GP consult 21 years Breast Screening Restless leg syndrome, IBS, depression
18(21) F / 45–49 Lymphoma GP consult 8 years Breast GP consult Early menopause
19(22) M / 65–
69
Bladder GP consult 1 year Prostate Incidental – via FPC Diabetes, high blood pressure, high
cholesterol
20(23) F / 50–54 Melanoma GP consult 22 years Breast, then
Thyroid
Incidental Thyroid problems
★Of 23 people interviewed, 20 met the final inclusion criteria
Table 2 Patient interviews: additional quotes
Themes Supporting quotes
Awareness of SPC “Interviewer: Did anybody ever mention to you about the risk of a second primary cancer or was it ever on your mind…?
P16: Never, no, no, I didn’t think at all. “P13




“…Very tired, […] I’m sitting at nine o’clock sleeping, and I thought this is not normal. So, I went to see my GP and they
took blood tests and then sent me for an X-ray, and that’s when they discovered that I had a tumour in my lung.” P1
“I’m probably less inclined to just sit on
something and not go to the GP, as a result.”
P18
Pathways to diagnosis of
SPC
“I will be absolutely frank, I never thought, oh goodness, that’s the second time I’ve had cancer […].[…]. That wasn’t the
first thing that came to my mind. I would say it took me quite a long time to kind of clock that actually, that means I’ve
had cancer twice. It just wasn’t top of my list of priorities to be perfectly honest.” P5
Navigating the healthcare
system
“I go to that urology clinic, it’s packed, it’s absolutely mobbed. It’s a really busy place […]. When I went to the kidney clinic,
when I first got it, there was only me, you know, there wasn’t a big queue or nothing.” P4
Impact of SPC “Interviewer: Have they ever mentioned your first cancer, the melanoma or was that kind of never discussed?
P5: Not really discussed, I mean they knew, but it wasn’t linked and nobody kind of majored on it.” P5
Cumulative burden of SPC “I thought, oh, no, here we go again.” P8
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Symptom appraisal and help-seeking
Pathways to diagnosis described by participants have a
marked similarity to those of a FPC.
In the case of those who had symptoms, participants
reported that they responded to these by telling their GP
or FPC consultant very quickly,
“..If this was a completely isolated, never had breast
cancer before, I think I would have reacted the same
way. I think I would have had that feeling of, some-
thing’s not quite right here.” P16
Participants also reported similar barriers and facilita-
tors to those reported elsewhere in relation to pathways
to diagnosis of a FPC, including issues such as normalis-
ing symptoms (e.g. attributing them to age or other on-
going comorbidities), work demands, masculine identity,
and being encouraged by family members to seek help,
“But, men don’t bother as much as, […] I don’t
think.” P1
There is a suggestion in the data that the help-seeking
interval in the pathway to diagnosis may have been ex-
pedited as a result of their previous cancer. A number of
participants reported, on reflection, a quick and some-
times urgent response in seeking advice from a HCP be-
cause of their previous cancer diagnosis,
“The last thing with my history is to leave it.” P2
Similarly, some participants could have had their help-
seeking and diagnostic intervals expedited by seeking
help when at an FPC appointment,
“I noticed the lump. And I was due to see the nurse a
few days later to take bloods. And I said to her, look
what do you think? And she said, I think you should
be seeing the doctor. […] It was a doctor I’d never met
before […] But she said, right I’m referring you straight
to the breast clinic at the [HOSPITAL].” P2
And while overall participants suggest that first pri-
mary cancers were not taken into consideration, some
participants perceived that it did influence their care sec-
ond time around,
“I think because I’ve had cancer before that when I
get appointments in the hospital they’re pretty
quick.” P4
Pathways to diagnosis of SPC
Routes to diagnosis varied among participants, with
roughly half of diagnoses as a result of a GP referral
following primary care attendance (see ‘Mode of Detec-
tion’, Table 1). The remaining half were picked up via
screening or in secondary care whilst attending for
follow-up of the FPC, both in the presence and absence
of symptoms.
Participants could be roughly divided into two groups
in the lead up to their SPC diagnoses. The first describe
a fairly direct and uncomplicated path between one can-
cer diagnosis and another, often with many years be-
tween diagnoses and no lasting effects of their FPC
following successful treatment,
“So I reacted quite quickly and I got an appointment
with my GP and my GP was excellent. They did an
internal […] and she sent me for an urgent colonos-
copy and I got that the following week.” P16
For this group, the first cancer is reported as some-
thing in the past that was treated and doesn’t have a
lasting physical impact on their lives. The second cancer
has come as a shock and was not expected.
For the second group of patients, the route between
diagnoses was less straightforward and people were often
dealing with recurrences, long-term side effects of first
cancer treatment (e.g. stoma) or significantly disabling
comorbid conditions,
“I didn’t have time to worry about it ‘cause it was
always… my ileostomy [as a result of first primary
bowel cancer] that takes over. And I have to just live
my life to keep that working properly without worry-
ing whether my breast cancer is going to come back
again or not.” P2
This group of patients is more likely to be in regular
contact with healthcare services for ongoing treatment
and review. While still unexpected and unwanted, the
impact of the SPC can be considered to have had less of
an impact on already turbulent circumstances.
Navigating the healthcare system
Previous experience of cancer did mean that participants
knew, to a degree, what to expect and, in many cases,
found the practical element easier second time around.
People were more familiar with the process and navigat-
ing the health care system,
“But as I say, I think because of previous experiences
and knowing the system and everything, I was able
to just rationalise it pretty quickly and say, this is
stupid. […] I could apply colorectal to the problem,
but obviously it wasn’t exactly the same. But it gave
me, sort of, insight and, you know…so that I wasn’t
so worried […].” P2
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Respondents also observed changes in health care ser-
vices, contrasting their two experiences of cancer, par-
ticularly when a long time had elapsed between
diagnoses. While acknowledging that treatment and
technological advances had been made, people perceived
a busier, resource-constrained environment, with more
pressure on staff to meet demands. They described
crowded waiting rooms, longer waiting times and diffi-
culties getting appointments in primary care,
“I feel really disappointed […] I think it’s just chan-
ging times, isn’t it? […] When I was going through all
the pancreas things, for a long time after, my GP
was amazing. She insisted I went to see her. […] This
GP I’ve got now hasn’t even acknowledged that I’ve
had breast cancer.” P8
While participants praised the NHS and the quality of
interpersonal care, they suggested that overall quality of
care has suffered as a result of the demand on services,
harking back to a time when there was better communi-
cation and good continuity of care.
Impact of SPC
The impact of a second primary cancer varied according
to time between and since diagnoses; type, stage and se-
verity of cancer; symptoms experienced; and treatment
and side effects. The impact of an early stage cancer
treated through surgery alone was less than that of
chemotherapy and radiotherapy, and with long term
consequences of treatment. For participant 14, not hav-
ing to go through chemotherapy for his second cancer
lessened the impact on his life considerably, despite hav-
ing to live with a stoma,
“They operated the next day, and they took out a
tumour which turned out to be a Dukes’ A. […] I
convalesced for about two weeks and then I went
back to work. […] It was just straightforward, in for
the operation, and I had a stoma, and it wasn’t too
bad, you know. It wasn’t too bad because I never
had chemo, this time.” P14
The perceived relevance of FPC on SPC diagnosis
varied between patients. Patients reported viewing
their cancer diagnoses as separate events, interpret-
ing their relevance to each other in the biological
sense of having cancer in two different anatomical
areas. However, the emotional relevance of each
diagnosis was discussed,
“No, they’re separate events, definitely. I definitely
feel they’re separate events but I still feel…I still
worry about the pancreatic cancer. That’s never, ever
left me, that worrying about that. Yes, I would say I
am worried about the breast cancer but, yes, it’s two
different worries, isn’t it?” P8
Most patients report no mention of their previous can-
cer diagnosis by HCPs during their SPC journey; the pa-
tients were often the first to raise the issue.
However, the impact on daily life differed from consid-
erations of the psychological impact of having cancer
twice, which could not always be accounted for in the
same way.
Cumulative emotional burden of a SPC In some re-
spects, the emotional experience of a second cancer was
similar to that of the first: the shock of diagnosis, strug-
gling to make sense of what was happening, fear of re-
currence and associated distress and worry,
“No, it’s still just a massive blow when you’re told
and you still go through the same shock, horror, why
me, and surely this can’t be happening, not for a sec-
ond time.” P15
Participants appeared to use similar approaches to
coping and adjustment through narratives of luck, hope
and upward social comparison (“Other people are dying
with it so I am lucky in a way” P4). However, there is
evidence that going through cancer a second time added
to the emotional burden of distress, worry and fear re-
lated to a cancer diagnosis.
“I thought, you know, you’re quite blasé about it,
you’re not expecting to get a second one. That really
takes the wind from you. […] Quite devastating.”
P10
The findings suggest that previous experience of can-
cer heightens the long term emotional impact and amp-
lifies the fear of recurrence.
“It does make you more aware of everything, you
know. […] It does…which I wasn’t a worried person
before, and it does make me more, everything now,
oh gosh, what’s this, you know.” P6
It is also important to consider the emotional and psy-
chological impact on family members in addition to the
patients themselves. This is something that was raised
by a number of participants,
“I try to protect them from it because I felt that
they’d had enough. Yes, in some ways I feel like
it’s been…if this had been the first time…this sec-
ond cancer had been the first time I had had
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cancer, I think that everybody’s attitudes would
be a lot different.” P8
Fear of a third primary cancer A unique concern that
builds on fear of recurrence commonly experienced
by people who have experienced SPC is the fear of a
third primary cancer. A number of participants voiced
worries that if they could be unlucky enough to have
cancer twice, they were aware that it could happen a
third time, adding to their distress and anxiety,
“No. I mean, it’s made me think about it now, now
that I know, you know, I’m maybe a bit paranoid if
you like, oh, I’ve had it twice, is it going to come back
again, you know.” P17
GP interviews
Seven GPs were interviewed, coming from a range of
practice sizes and locations, including one female and
six male GPs, and with varying levels of practice experi-
ence ranging from 3 to 25 years (see Table 3). The key
findings from the GP interviews relate to awareness of
and detection of SPC as reported below.
Experience and knowledge of SPC
GPs interviewed perceived SPCs as very rare and de-
scribed never before or rarely encountering them in
their clinical practice. Their focus was more likely to be
on recurrence of an FPC,
“First we would probably think, is this a recurrence
of the primary cancer [..], rather than a new diagno-
sis of another type of cancer.” GP6, 6–10 years’
experience
GPs reported not always knowing about the previous
cancer. Time constraints, lack of continuity of care and
time since the previous diagnosis often meant the FPC
wasn’t coded on their electronic record or the GP didn’t
have time to read it prior to consultation. While GPs felt
they should know, it wasn’t always the case, and the
onus was often on the patient to bring it up.
“I would say it’s very rare. I mean we might not even
identify that they’ve had a previous cancer; it might
not be relevant.” GP 1, Under 5 years’ experience
GPs reported that SPCs were not something they gen-
erally thought about (although time between diagnoses
influenced this), or discussed the relative risk of with
their patients. One GP considered that it was something
they perhaps should be more aware of,
“It’s just a little lightbulb moment for everybody and,
I guess, raising awareness of it... if nobody says any-
thing out loud then it maybe just doesn’t occur to a
lot of us.” GP2, 21–25 years’ experience
Decision-making and referrals
Similar to the findings from patient interviews, GPs de-
scribed their decision-making around suspicion of can-
cer and referral as very similar to those of a first cancer.
As with patient reports, SPCs are considered as unre-
lated to first primaries. GPs report that they respond to
symptoms (particularly red flag symptoms) and make re-
ferral decisions accordingly,
“I mean hopefully we refer people all fairly urgently”
GP 7, 31–35 years’ experience
“So it’s more decided on presenting symptoms rather
than what happened in the past.” GP3, unknown
experience
However, one GP discusses individual variation and
the distinction between biological and psychosocial im-
pact of experiencing cancer for a second time; thus
recognising the importance of acknowledging previous
experience of cancer,
“I mean I think the two are probably related; I think
they have the same sort of impact upon people’s kind
of psyche and things. So I mean I wouldn’t necessar-
ily associate the causality between the two of them,
but I think from the patient’s perspective, they’ve got
Table 3 GP Characteristics
GP identifier Years’ experience Health Board/ relevant practice characteristics
GP 1 Under 5 years Lothian, large practice, 6 GPs
GP 2 21–25 years Tayside, large urban practice
GP 3 Unknown Lothian, large semi-rural practice
GP 4 16–20 years Lothian, small, semi-rural, some deprivation.
GP 5 21–25 years Lothian, urban practice
GP 6 6–10 years Tayside, small rural practice
GP 7 31–35 years Borders, mid-size practice, semi-rural
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cancer, it doesn’t really matter whether it’s one or
two.” GP5, 21–25 years’ experience
The same issues arise as around the challenges of
diagnosing first cancers in primary care, particularly
when patients are frequent attenders or have multi-
morbidity clouding their cancer symptoms and in a
resource constrained environment with competing
priorities for patient care. Access to investigations




This study reports the views and experiences of patients
with SPC and their GPs, examining whether having pre-
vious first-hand experience of cancer influences one’s
subsequent pathway to diagnosis. Patient participants re-
ported that they hadn’t thought about getting a second,
different cancer. Their symptom appraisal and help-
seeking patterns were very similar to those for FPC, but
with some suggestion that having a previous cancer did
influence their decision-making. Patient experiences
were varied, reflecting different cancer types, stages and
severity of disease, and time between diagnoses. People
had their second cancer detected in both primary and
secondary care, both in response to and in the absence
of symptoms, prompted by their help-seeking or an inci-
dental finding. These incidental diagnoses are of interest,
considering these cancers may not otherwise have been
detected at this time and it is possible patients may not
have consulted with symptoms, lengthening the patient
interval prior to referral and diagnosis. However, partici-
pants do not explicitly refer to whether they felt being
‘in the system’ for follow-up made a difference.
Previous practical experience of navigating the health
care system appeared to lessen anxiety as a result of fa-
miliarity. However, the psychological burden of SPC ap-
peared to have a cumulative effect on people’s emotional
responses, especially where treatment was more invasive
and had a bigger impact on people’s lives, including
those of loved ones. Moreover, knowledge of SPC raised
concerns of the risk of third primary cancer, despite this
risk being minimal.
GP accounts of diagnosing second cancers echo
those of patients in reporting low awareness and a
similar response to that of symptoms of FPC. GPs
stated that they did not think of SPCs before receiv-
ing the study pack and were more vigilant for recur-
rence than SPC. However, they responded to red flag
symptoms in the same way as they would for FPC.
SPC detection is one challenge of many in the
current climate of primary care.
Comparison with existing literature and theory
Few qualitative studies report experiences of SPC. Shin
and colleagues in Korea have explored patient and on-
cologist perspectives on SPC surveillance and describe
very similar narratives on rarity and lack of awareness
[5, 24]. However, past experience is likely to be more
embodied and the influence of a previous cancer on peo-
ple’s behaviour more complex to tease out.
There are a number of barriers and facilitators to con-
sider in terms of factors influencing help-seeking behav-
iour on the pathway to diagnosis. Previous experience
has been highlighted as a factor influencing symptom
appraisal and help-seeking in the Pathways to Treatment
model [14]. Having prior, personal, experience of cancer
appears to emphasise the role of this factor. Participants
in our study may be more aware of cancer and early de-
tection as a result of their treatment and conversations
with specialists, as well as public health campaigns.
However, fear of the known and resulting avoidance has
been identified as a barrier to help-seeking elsewhere in
the literature [25]. Nevertheless, patients in this study
did allude to the fact that they were less likely to ‘sit on
things’ due to their past experiences. It is worth noting
that this participant group were people who had mostly
been successfully treated for a previous cancer and most
did not have advanced disease; responding more quickly
to symptoms may therefore not apply to those with
more advanced illness. Previous experience of cancer
and moving through the healthcare system may impact
on speed and likelihood of responding to symptoms, and
there is some evidence in our data to support this claim,
but more detailed exploration of this aspect of health be-
haviour is required. We would suggest that findings on
diagnostic intervals be interpreted in the context of this
group of interviewees and transferability to the average
patient with SPC should be done with caution. Further
large scale data is needed to compare diagnostic inter-
vals between first and second and subsequent primary
cancers.
The role of procedural knowledge (gained through ex-
perience of navigating the health care system) in lessen-
ing distress resonates with the information literature e.g.
[26]. Having acquired general knowledge of how depart-
ments work and what to expect from surgery and recov-
ery through past experience, albeit for a different cancer,
embeds information and removes the uncertainty associ-
ated with anxiety and distress [27]. While past experi-
ence does not appear to wholly take away the shock and
distress of SPC diagnosis, it may moderate it.
GP interviews suggest that their suspicions of cancer
are no different for second primaries than for first can-
cers. They report responding to alarm symptoms as the
primary indicator prompting referral for investigations,
similar to other studies focused on early detection in
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primary care [28]. The role of a previous cancer appears
to be minimal in the present study; yet it has been
highlighted as key, along with presenting symptoms, in
increasing suspicion of cancer in a survey with Norwe-
gian GPs [29]. GPs discussed the challenges of diagnos-
ing cancer in primary care - such as lack of resources,
vague symptoms and comorbidities – as described in
other studies [30, 31]. However, in contrast to other
studies, patients in this study did not report long delays
and multiple consultations prior to second diagnosis
[32], with potential implications for patient outcomes
[33]. The focus on reported symptoms suggests that
current research and interventions to understand, im-
prove and support GP decision-making and referrals, as
well as tackling psychological barriers to patient access
to healthcare, are also relevant to early detection of SPC,
as reported elsewhere [34–38]. These findings suggest
that previous first-hand experience of cancer has a nu-
anced role in the decision-making process and there is
scope for its addition to existing models of patient
behaviour.
Cancer, whether it be a first or second diagnosis, ap-
pears to have a greater impact for participants if it brings
more symptoms, more invasive treatment and limita-
tions on functionality as a result of the lasting effects of
surgery, chemotherapy and radiotherapy. These are the
hallmarks of the cancer journey and embed cancer
patienthood more forcefully, with a greater degree of
disruption to daily life and personal identity or ‘bio-
graphical disruption’, for the patient and their family,
and the quest for a new normal [29, 39–41]. The level of
disruption, when also hit with a second cancer and po-
tentially comorbid conditions as well, is heightened,
though there may be scope for ‘procedural knowledge’
to moderate distress.
Implications for research and practice
There are implications, therefore, for people’s ability to
process the cumulative emotional burden and adjust to
their illness and personal identity. Patients and GPs re-
ported that previous cancers did not feature in discus-
sions of their most recent cancer, but the emotional
impact of previous experience was pronounced. While
a previous cancer may not be significant in terms of
diagnosing subsequent cancers (apart from known
treatment-related or genetic links), it is clear that ac-
knowledgement and discussion of past experiences and
future risks holds psychological significance for pa-
tients’ subsequent coping and adjustment [3]. It is ne-
cessary, therefore, to consider the role of this
conversation in survivorship care provided in primary
care spaces [15, 17, 18].
We recommend the following: The risks of SPC
should be sensitively communicated to cancer survivors;
psychological support should be offered alongside con-
versations of risk and fear of recurrence to manage the
emotional impact of a second primary cancer for pa-
tients and their families; SPC can be incorporated into
the ‘past experience’ dimension of the Pathways to
Treatment model to understand the journey to diagnosis
of SPC; and existing efforts to detect cancer at an early
stage and improve patient outcomes can be applied to
SPC in their current form.
Strengths and limitations of the study
This study provides unique insights to the experiences
of people who have been diagnosed with cancer for a
second time, and for the GPs diagnosing them. This rich
data can help to unpick the behavioural aspects of the
pathway to diagnosis of SPC, to complement the body of
evidence presenting incidence, risk and survival. This
study provides some interesting findings to a group of
early detection researchers expecting to find differences
in the way patients and professionals respond to symp-
toms of an SPC. In fact, the pathways are very similar,
providing important evidence for early diagnosis
research.
Patient interviews come from a self-selecting group
of invited participants who may have above-average
health; long-term survivors are more likely to be re-
cruited in studies such as this. While this study pro-
vides important evidence that is transferable to those
who have survived a first cancer and are doing well,
we may be missing the voice of those with advanced
and end of life disease, for whom the pathways to
diagnosis may be very different and/or difficult. Par-
ticipants’ experiences are also captured relatively soon
after diagnosis and so a longitudinal design may have
offered different insights over time. Finally, this inter-
view study is conducted with those who self-selected
to take part and therefore findings cannot be assumed
to be transferable to the broader population of cancer
survivors; caution in interpreting the results is war-
ranted. Abel and colleagues have explored characteris-
tics of responders and the role of non-response in
UK-wide cancer patient experience survey [42].
Recruitment of case-linked GP interviews proved chal-
lenging and resource issues resulted in a small number
of GP interviews being achieved. While worthwhile find-
ings with strong conformity have been obtained, findings
are limited in their transferability and should be inter-
preted in the wider context of early diagnosis and pri-
mary care research.
Conclusions
Awareness of the risk of second primary cancer is low
among cancer patients and GPs involved in cancer sur-
veillance. However, synchronous reports from patients
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and GPs about symptom appraisal, help-seeking and re-
ferral for suspicions of cancer being very similar for first
and second primary cancers suggest that current efforts
to expedite diagnosis of cancer are as applicable to SPC
as to FPC. Evidence to suggest a cumulative psycho-
logical burden of second primary cancer and fear of
third primary highlight the need for past experiences of
cancer to be part of the conversation and risks of subse-
quent cancers sensitively discussed.
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